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A B S T R A C T
Objectives: Use of point-of-care testing is increasing, however many haematology analysers can
only determine granulocyte count without further diﬀerentiation into neutrophils, eosinophils
and basophils. Since the diagnosis of life-threatening neutropenia in cancer patients requires a
distinct neutrophil count, this study aimed to determine the comparative performance between
the neutrophil and granulocyte count.
Design and methods: A database of 508 646 venous full blood count results measured on a la-
boratory reference analyser was mined from a large oncology unit. The relationship between
granulocyte and neutrophil counts was assessed. Multinomial logistic regression was used to
classify results into neutropenia grades using an equivalent granulocyte count.
Results: Granulocyte to neutrophil count correlation was 0.997. The accuracy for classiﬁcation
into neutropenia grades using the derived equivalent granulocyte count ranges was 96.4%.
Identiﬁcation of results with a neutrophil count< 1.5×109 cells/L using an equivalent granu-
locyte count of< 1.69×109 cells/L resulted in sensitivity, speciﬁcity, positive and negative
predictive values of 98.0%, 99.5%, 97.8% and 99.5%, respectively.
Conclusions: These results describe the relationship between granulocyte and neutrophil counts,
measured on a laboratory analyser, in a large population of patients with malignancies and re-
ceiving anti-cancer therapies. However, this relationship must be established using a point of care
testing system with a three-part diﬀerential count before considering the possibility that a
granulocyte count can guide clinical decisions in the absence of a deﬁnitive neutrophil count, to
reduce the frequency and severity of neutropenic complications in patients receiving cancer
treatments.
1. Introduction
The technology of morphological assessment and counting of blood cells has advanced over recent decades, particularly in the
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white cell lineage, with concomitant beneﬁts in relation to diagnosis, prognosis and management of inﬂammatory and malignant
conditions. The full range of measurements is available on modern automated laboratory analysers. However, dependence on a
service provided by a central laboratory has certain limitations, with potential clinical, operational and economic implications. These
issues could arise in any setting where rapid decision making is required, e.g. the Emergency Department, primary care, a para-
medical rural service, an out-of-hours doctor service or in the home, as well as in middle- and low-income countries [1–5].
One of the major technological advances has been in the recognition and quantiﬁcation of diﬀerential white count. The initial
three-part diﬀerential count expanded to the ﬁve-part diﬀerential count, with diﬀerentiation of the granulocyte count into neu-
trophil, basophil and eosinophil counts. Viral and bacterial infections are arguably the most common cause of acquired neutropenia
[6,7], through margination of neutrophils and destruction by circulating antibodies [8]. Neutrophil levels may also be decreased due
to congenital haematological malignancies [9], as a result of radiotherapy [10] or through the use of cytotoxic chemotherapy drugs
[11]. Extreme reductions in neutrophil count can lead to serious complications such as febrile neutropenia (fever> 38°C and neu-
trophil count< 0.5×109cells/L [12]), increasing the risk of sepsis-associated mortality [13], necessitating urgent clinical assessment
in at risk patients. Thus, most chemotherapy patients are given immediate empirical antibiotics upon suspicion of infection [14]. In
such patients, access to a rapid diﬀerential white count is vital as delays in administration of broad-spectrum intravenous antibiotics
are associated with increased mortality risk, but overtreatment with unnecessary antibiotics has opportunity costs [15].
Access to the absolute neutrophil count (ANC) can be diﬃcult in the early phase of developing neutropenia in patients on
chemotherapy. These patients tend to be at home, and a health-care professional is required to obtain a venous sample from fre-
quently accessed veins which need to be preserved for delivery of chemotherapy, but are often already compromised by vesicant and
irritant cytotoxic drugs. Thus, it is not routine practice to monitor the neutrophil count during the chemotherapy cycle unless the
patient reports symptoms suggestive of developing severe neutropenia complicated by infection.
There have been very few studies comparing the diagnostic performance of granulocyte and neutrophil counts in patients re-
ceiving chemotherapy. The aims of this study were to (i) determine the threshold of total granulocytes which represents a neutrophil
count which signals a change in patient management, and (ii) determine if total granulocytes could be used as a meaningful indicator
of neutrophil count in the neutropenic range for cancer patients receiving chemotherapy. This study was the ﬁrst step in determining
whether it was valid to consider the use of a granulocyte count for monitoring patients receiving chemotherapy.
2. Material and methods
2.1. Study design and patient selection
Analysis was conducted on a pseudonymised, retrospective database containing peripheral venous blood sample results between 1
January 2004 and 1 September 2013 from 21,020 patients, all of whom had received chemotherapy treatment at the Leeds Cancer
Centre, Leeds Teaching Hospitals Trust (LTHT). The LTHT results server receives blood test results from the pathology laboratories
and displays them in the electronic patient recording system (Patient Pathway Manager (PPM)) [16,17]. A pseudonymised extract
was taken and inserted into a research database. No identiﬁable data was contained within the dataset and the research was
sanctioned under the information governance procedures of LTHT, with data extraction pseudonymisation procedures as agreed with
the Caldicott Guardian and with formal approval from a national research ethics committee (NHS Grampian ID: 13/NS/0128). No
patients were excluded based on their chemotherapy treatment, demographic information, diagnosis or timing of treatment.
Blood counts were measured from EDTA venous whole blood samples obtained for the purposes of routine clinical care, and taken
at any time in relation to chemotherapy delivery. All samples were submitted for a full blood count analysis, including a ﬁve-part
diﬀerential on a Siemens ADVIA 120 analyser (Siemens Healthcare Diagnostics, Erlangen, Germany) until August 2004 and subse-
quently on the Siemens ADVIA 2120 analyser; both instruments employ the same method principles. All instruments were subjected
to multiple quality control (QC) checks each day according to standard laboratory protocols, and the laboratory participated in the
United Kingdom National External Quality Assessment Service (UKNEQAS) external quality assurance scheme.
Data of interest included the eosinophil, basophil and neutrophil counts, with the sum of these three parameters being taken as
the granulocyte count (calculated in Microsoft SQL Server). Lymphocyte and monocyte results were also extracted for analysis. As
within-day timing information was not available, if a patient had more than one blood test on a given day all data for that day was
excluded to avoid ambiguity as to which result should be taken as the true value for that day.
2.2. Correlation and regression analysis
The R programming language package was used to conduct all statistical analysis and produce all ﬁgures [18]. Pearson's product-
moment correlations were used to measure the strength of the linear association between complete granulocyte count and each of its
components (eosinophils, basophils and neutrophils); p<0.05 was considered signiﬁcant. To correct for the diﬀerences in scale, raw
count data was log transformed and standardized (x′= [ln {x}- mean (ln {x})]/ standard deviation (ln{x}). Passing-Bablok regression
analysis was conducted using the MCR package for R [19]. This was performed separately on subsets of individuals with neutrophil
counts classiﬁed as N0-N1 (normal to grade 1 neutropenia,≥ 1.5 to≤ 7.5 × 109 cells/L) and N2-N4 (grade 2–4 neutropenia, < 1.5
× 109 cells/L) using grading criteria deﬁned by The Common Terminology Criteria for Adverse Events [20]. To limit the memory
requirements and computational overhead, the regression analysis was on a random subset of 32,000 results in each subset.
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2.3. Diﬀerence analyses
Bland-Altman plots were constructed in order to assess the relation between neutrophil and total granulocyte count [21] where
the diﬀerence between measures is plotted against the average of the two measurements. Good concordance can be concluded if
enough points fall within narrow limits of agreement, to be conﬁdent that one method could be used in the place of another i.e., the
mean diﬀerence should be close to zero and at least 95% of diﬀerences should not exceed 1.96 standard deviations (SD).
2.4. Classiﬁcation into neutropenia grades
The data was divided using random split sampling (1:2) into derivation and validation datasets. Multinomial logistic regression
using the VGAM package [22] was employed on the derivation data to derive equivalent granulocyte count ranges to classify each
neutrophil result by neutropenia grade (as deﬁned above). Model performance measures were reported for the validation dataset at
each neutrophil classiﬁcation section grade and it was also assessed on its ability to identify N2–N4 neutrophil results. Finally this
threshold was adjusted using optimised values for speciﬁc objectives using the ‘Optimal Cutpoints’ package [23].
3. Results
3.1. Data distribution
There were 508,646 test results with only one neutrophil, eosinophil, basophil, monocyte and lymphocyte count result per patient
per day. The distribution of count results for complete granulocyte and each of the diﬀerential counts was assessed (Fig. 1). The total
number of results within the reference range was 258,363 (50.8%) for neutrophils (2.5–7.5 × 109 cells/L), 329,179 (64.7%) for
eosinophils (0.04–0.4×109 cells/L) and 436,970 (85.9%) for basophils (0.01–0.1 × 109 cells/L). In total, 187,003 (36.8%) results
fell within the reference range for eosinophil, basophil and neutrophil results and there were 404,935 (79.6%) results within the
upper limit of normal for all three granulocyte components. When considering granulocytic disease states, 172,266 (33.9%) of results
had neutropenia (< 2.5 × 109 cells/L), 78017 (15.3%) neutrophilia (> 7.5 × 109 cells/L), 158,353 (31.1%) eosinopenia (< 0.04 ×
109 cells/L), 21,114 (4.2%) eosinophilia (> 0.4 × 109 cells/L), 50,311 (9.9%) basopenia (< 0.01 × 109 cells/L) and 21,365 (4.2%)
basophilia (> 0.1 × 109 cells/L).
3.2. Correlation and regression
It is acknowledged that neutrophils are the largest component of granulocytes; however, the extent of this relationship and that to
the other diﬀerentials was investigated with a view to predicting neutrophil count. Correlation coeﬃcients compared to the neu-
trophil count were found to be 0.997 for granulocytes (R2 = 0.995), 0.203 for eosinophils (R2 = 0.041), 0.248 for basophils (R2 =
0.062) and 0.266 for eosinophils plus basophils (R2 = 0.071). To lessen the eﬀects of skew and diﬀerences in scale, analysis was also
Fig. 1. Distribution of cell count results for total granulocytes and individual diﬀerentials. Histograms of 508646 results for (A) granulocytes (x 109 cells/L) (minimum
= 0; maximum = 213.42, median = 3.73; mean = 4.65; standard deviation (SD) = 4.31; (B) neutrophils (x 109 cells/L) (minimum = 0; maximum = 180.58,
median = 3.55; mean = 4.49; SD = 4.21); (c) eosinophils (x 109 cells/L) (minimum = 0; maximum = 53.69, median = 0.07; mean = 0.12; SD = 0.26); (d)
basophils (x 109 cells/L) (minimum = 0; maximum = 51.43, median = 0.03; mean = 0.04; SD = 0.15).
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conducted using standardised natural logarithmically transformed values. Although correlations improved upon transformation,
overall they remained weak for eosinophils and basophils (0.998 for granulocytes, 0.405 for eosinophils and 0.452 for basophils).
Passing-Bablok regression between granulocyte count and neutrophil count was performed in two groups according to neutrophil
result: N0-N1 (normal or grade 1 neutropenia, neutrophils 1.5–7.5 × 109 cells/L, n = 331977) and N2-N4 (grade 2–4 neutropenia,
neutrophils< 1.5 × 109 cells/L, n = 98652). Fig. 2 illustrates both results. All data pairs lie necessarily below the identity line and
are in fact highly concentrated around the regression line, with some spread of outliers below the regression line. Slopes and intercept
with conﬁdence intervals are summarized in Table 1.
3.3. Diﬀerence analyses
As previously, counts were split into N0-N1 and N2-N4 results. Fig. 3A shows that 97.9% of results had a granulocyte count not
exceeding the neutrophil count by more than 0.600 × 109 cells/L (the upper limit of agreement). In other words, the sum of only
7048 out of 331,977 eosinophil and basophil counts exceeded 0.600 × 109 cells/L. Investigation of the N2–N4 results revealed only
2338 results out of 98652 (2.4%) had a granulocyte count exceeding the neutrophil count by more than 0.265 × 109 cells/L (Fig. 3B).
Analysis on individual neutropenia grades revealed 97.0% of grade 1 results had a diﬀerence of less than 0.358×109 cells/L (mean
0.111), 96.6% of grade 2 results were<0.278 × 109 cells/L (mean 0.086), 97.2% of grade 3 results were< 0.242 × 109 cells/L
(mean 0.066) and 97.5% of grade 4 results< 0.140 × 109 cells/L (mean 0.026).
3.4. Classiﬁcation
Agreement analysis found a relatively small mean diﬀerence for both the N0-N1 and N2–N4 neutrophil result ranges. Therefore,
the ability to correctly classify neutropenia grades using an equivalent granulocyte count range was investigated. The complete
dataset was randomly split (1:2) into derivation (n= 167,853) and validation (n= 340,793) subsets on which a multinomial logistic
regression classiﬁer was trained and tested, respectively (Supplemental data, Fig. 1).
An equivalent granulocyte range was derived by the classiﬁer for each neutrophil determined grade (Table 2), achieving an
accuracy of 96.4%. Classiﬁcation of results within the reference range using granulocyte counts between 2.64 and 7.72 × 109 cells/L
was correct 98.1% of the time but incorrectly included a grade 1 neutropenia result in 1.2% of cases. The equivalent grade 1 count
(1.6–2.63 × 109 cells/L) was correct for 93.0% of its predictions but had a 2.6% chance of misclassifying a grade 2 neutropenia
result. The worst performance, positive predictive value (PPV) of 88.5%, occurred when identifying grade 2 neutropenia (1.08–1.60
× 109cells/L) with a 4.9% chance of identifying grade 3 neutropenic patients and 2.7% displaying grade 4 neutropenia. Identiﬁ-
cation of grade 4 neutropenia using a granulocyte cut-oﬀ at 0.56 × 109cells/L resulted in a PPV of 97.5% but had a 2.5% chance of
Fig. 2. Relationship of neutrophil and granulocyte counts for (a) normal and neutropenic grade 1 (neutrophil count 1.5–7.5×109cells/L), (b) neutropenic grades 2–4,
neutrophil count< 1.5 × 109cells/L).
Table 1
Slopes and intercepts, and their respective conﬁdence intervals, from the Passing-Bablock regression of granulocyte and neutrophil counts, grouped according to
neutropenia grades.
Intercept CI Slope CI
N0-N1 −0.071 −0.074, −0.068 0.984 0.983, 0.985
N2-N4 −0.0063 −0.0068, −0.006 0.954 0.953, 0.955
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Fig. 3. Diﬀerences analysis for (A) normal and neutropenic grade 1 and (B) neutropenic grade 2–4 results. Bland-Altman plots showing (A) N0-N1 results (neutrophil
count 1.5–7.5×109cells/L), n = 331977 and (B) N2-N4 results (neutrophil count< 1.5 × 109cells/L), n = 98652. Grey dashed lines from top to bottom: upper limit
of agreement (+1.96 SD) (A) 0.600, (B) 0.265; average diﬀerence (A) 0.174, (B) 0.058; lower limit of agreement (−1.96 SD) (A) −0.252, (B) −0.149; critical
diﬀerence (A) 0.427, (B) 0.207. Note the lower limits are redundant since diﬀerence cannot be less than 0. Points plotted with a transparency alpha of 0.01.
Table 2
Classiﬁcation of the validation dataset (n = 340793) into neutrophil grades using an equivalent granulocyte count.
Grey boxes indicate correctly identiﬁed results. Sn, sensitivity; Sp, speciﬁcity; PPV, positive predictive value; NPV, negative predictive value.
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including a grade 3 neutropenic patient.
In addition to the multinomial classiﬁcation above, we also investigated binary classiﬁcation with single granulocyte count
boundaries.
The ability to correctly distinguish between N0-N1 results (1.5–7.5 × 109 cells/L) and N2-N4 neutropenia (< 1.50 × 109 cells/L)
was assessed using various cut points. Maximising the product of sensitivity and speciﬁcity resulted in a threshold of< 1.69 × 109
cells/L, and excellent discriminatory performance (Table 3), but 862 patients with a neutrophil count< 1.50×109 cells/L were
missed using this selection criterion. To achieve 100% sensitivity a threshold of< 2.39 × 109cells/L could be used, missing only 49
of the 98652 patients with ANC<1.50 × 109cells/L, but this is accompanied by a decrease in speciﬁcity (86.5%) and PPV (64.1%),
mistakenly including 55164 patients with ANC≥ 1.50 × 109 cells/L (10.8%). Use of a granulocyte count threshold of< 1.53 × 109
cells/L results in 100% speciﬁcity, mistakenly including only 129 of the 508646 patients with ANC ≥ 1.50 × 109 cells/L, but
predicting 4402 as normal/grade 1 neutropenia when they were more severely neutropenic (sensitivity 95.5%, PPV 99.9%, negative
predictive value (NPV) 98.9%).
The separation of results based on diﬀerent grade boundaries was also investigated (Table 3). Using the product of sensitivity and
speciﬁcity, capture of grade 3 neutropenia results (< 1.0 × 109 cells/L) can be achieved using a granulocyte count of< 1.13 × 109
cells/L to provide sensitivity of 98.9%, speciﬁcity of 99.2%, PPV of 95.2% and NPV of 99.8%. Grade 4 neutropenia results can be
discriminated using a threshold of< 0.62 × 109cells/L to give sensitivity 99.1%, speciﬁcity 99.3%, PPV 93.0% and NPV 99.9%.
3.5. Dataset restrictions
Exclusion of patients with eosinophilia (≥ 0.4 × 109 cells/L) or basophilia (≥ 0.1 × 109 cells/L) from the dataset (n = 469433)
improves the correlation of granulocytes to neutrophils with resulting R2 = 0.996 for the N0-N1 results and 0.988 for N2–N4
neutropenic patients. Agreement analysis resulted in 94.4% agreement with a mean diﬀerence of 0.192 (upper limit 0.335) and
94.9% agreement with a mean diﬀerence of 0.122 (upper limit 0.174).
When the dataset is restricted to include only patients that have received cytotoxic chemotherapy within 42 days (n = 279992),
the correlation again improves with R2 = 0.989 and 0.978 for N0–N1 and N2–N4 neutropenia patients, respectively. Furthermore,
Bland-Altman plots showed 97.1% agreement with a mean diﬀerence of 0.321 (upper limit 0.464) and 96.9% agreement at 0.164
(upper limit 0.216) respectively.
4. Discussion
A good correlation between granulocyte and neutrophil counts was observed, with a linear regression line almost identical to the
line of identity. This was maintained even when the neutrophil count was reduced to less than 1.5 × 109 cells/L, which is the
reference range most relevant to decision points in oncological practice. The Bland-Altman analysis indicated good agreement be-
tween granulocyte and neutrophil counts with 97.6% of granulocytes being within 0.265 × 109 cells/L of neutrophil counts when all
neutrophil counts were less than 1.5 × 109 cells/L. Furthermore, we presented the ﬁrst deﬁnition of granulocyte counts equivalent to
CTCAE neutropenic grades.
In clinical practice there would be little need to change management decisions based on the speciﬁc grade of neutropenia, but,
more likely, on which side of a speciﬁed threshold the patients’ neutrophil count falls. Therefore, we investigated the boundaries of
clinically relevant thresholds, identifying that if < 1.5 × 109 cells/L neutrophils is used, the best performing granulocyte count
would be<1.69 × 109 cells/L, and if< 1.0 × 109/L neutrophils is used, the best performing granulocyte count would be<1.13
×109 cells/L. Both of these scenarios had a NPV of 99.8% which translates into only 1 in 500 results which would be misclassiﬁed as
above the threshold.
International guidelines for the treatment of neutropenic fever recommend an ANC<0.5 ×109 cells/L as the threshold for
change in clinical management [24–29]. However, it should be noted that these guidelines assume a full clinical assessment is carried
out. Three-part diﬀerential analysers might have the potential to be used as point of care devices where the patient may be remote
Table 3
Classiﬁcation of neutropenic results using various granulocyte count thresholds.
Granulocyte Threshold (x109cells/L) TP (n) FP (n) TN (n) FN (n) Sn (%) Sp (%) PPV (%) NPV (%)
Grade 2–4 i) <1.53 94250 129 409865 4402 95.5 100.0 99.9 98.9
ii) <1.69 97790 6849 403145 862 99.1 98.3 93.5 99.8
iii) <2.39 98603 55164 354830 49 100.0 86.5 64.1 100.0
Grade 3–4 i) <1.03 66281 195 439569 2601 96.2 100.0 99.7 99.4
ii) <1.13 68155 3436 436328 727 98.9 99.2 95.2 99.8
iii) <1.71 68848 37051 402713 34 100.0 91.6 65.0 100.0
Grade 4 i) <0.51 42703 38 463844 2061 95.4 100.0 99.9 99.6
ii) <0.62 44361 3359 460523 403 99.1 99.3 93.0 99.9
iii) <1.15 44742 28437 435445 22 100.0 93.9 61.1 100.0
TP, true positive; FP, false positive; TN, true negative; FN, false negative; Sn, sensitivity; Sp, speciﬁcity; PPV, positive predictive value; NPV, negative predictive value;
n = 508646. Decision points chosen maximise (i) speciﬁcity (ii) the product of sensitivity and speciﬁcity (iii) sensitivity.
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from the clinician; therefore, this work analysed the performance of granulocytes with reference to neutrophil count thresholds
greater than 0.5 × 109/L to allow for safety margins required due to absent clinical information. The important clinical question is: if
using the equivalent granulocyte count indicates the patient has an ANC above the speciﬁed threshold, how sure can we be that this is
correct? As an example, using granulocyte count to indicate a neutrophil result is less than 1.0 × 109/L, the best performing
granulocyte count in terms of balancing false negatives with false positives would be<1.13 × 109/L, but in order to obtain no false
negative results, a signiﬁcantly higher threshold needs to be used. This would be oﬀset by increasing the false positives. It is a clinical
decision as to whether this is acceptable, and is dependent upon the consequences of misclassiﬁcation of a result. However, this
concept would have to be tested in an appropriate clinical trial setting with a point of care testing (POCT) system with a 3-part
diﬀerential measurement capability.
The strength of this data is the large cohort of patients employed in this analysis, with a wide variety of patients in terms of their
neoplasm diagnosis, other co-morbidities, demographic information and many possible neutrophil abundancies. All grades of neu-
tropenia are represented and this may be due to cytotoxic treatments such as chemotherapy or the cancer diagnosis itself.
However, these ﬁndings must be interpreted with considerable caution and there are a number of limitations that must be taken
into account when drawing conclusions from this work. Firstly, the methodology of granulocyte extraction by summating its dif-
ferentials is not a direct result from a haematology analyser and therefore may underestimate errors between readings. Secondly,
both measurements were made on a ‘state-of-the art’ haematology analyser in a central laboratory, albeit as part of routine daily
practice. Thirdly, there are recognised diﬀerences in the quantitation of individual white cell species with the use of diﬀerent
detection technologies. This means that variation in the counting technology due to cell population diﬀerences may impact on the
results, e.g., in the presence of blast or immature granulocytes or neutrophils.
We suggest it is technically feasible to use granulocytes, but this should always be after a baseline reference analyser neutrophil
count, to exclude patients at high risk of misclassiﬁcation on the wrong side of a speciﬁed decision threshold. Such high-risk patients
would include those with eosinophilia or basophilia, or active allergic conditions.
This study has considered the single result in the context of decision making; it is possible that such measurements may be used
for routine monitoring. We conclude from this large cohort of data that the granulocyte count warrants further consideration as a
surrogate indicator of neutrophil count. It could be used to indicate the CTCAE grade of neutropenia and its use could be considered
in patients with suspected febrile neutropenia, where an alternative neutrophil count may not be readily available. However, it must
be recognised that this relationship has been established with both measurements made on an established laboratory analyser system.
This relationship cannot be assumed to be applicable to laboratory analysers employing diﬀerent detection methodologies or to POCT
systems. Therefore, the ﬁndings from this study cannot be extrapolated to the POCT situation. If POCT, using a three-part diﬀerential
white count, is to be considered for monitoring patients on chemotherapy away from the hospital setting, then the relationship
between the granulocyte and neutrophil count must be established using the technologies that will be used in routine practice
[30–32]; with an appropriate cohort of patients exhibiting the range of neutrophil counts expected to be experienced, and as a
precursor to a clinical trial.
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